WASHINGTON (AFP) — US drug regulators have authorized the sale and use of a drug marketed as Evista to prevent aggressive breast cancer in post-menopausal women.
The drug, produced by US-based Eli Lilly, already has US Food and Drug Administration approval to prevent osteoporosis among postmenopausal women.
The approval “provides an important new option for women at heightened risk of breast cancer,” said Steven Galson, director of the US Food and Drug Administration’s Center for Drug Evaluation and Research. However, he cautioned that side effects are serious.
Most Popular
Public Speaking: 7 Secrets Of Great Public Speakers
5 Regular Mistakes In Public Speaking
10 Jobs That Pay $30 An Hour
3 Questions No Job Seeker Ever Wants To Be Asked?
13 Job Interview Mistakes To Avoid
Users of the drug must watch out …
Read the full article with a Free Trial at MyWire.